Schizophrenia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. taking Amisulpride monotherapy for at least 3 months; 2. stable mental state, stable treatment for at least 3 months, and PANSS scores was less than 60; 3. level of serum PRL was greater than 24 ng/mL; 4. at least one overt hyperprolactinemia-related symptom, including amenorrhea, abnormal menstruation, galactorrhea, reduced libido or sexless; 5. screening negative for pregnancy in women and agreed to use effective contraception methods during the study. The protocol of this study was approved by the medical ethical committee of Brains Hospital of Hunan Province. All participants and their guardians were given the voluntary, written, and informed consent before entering the trial.
Exclusion criteria
Exclusion criteria: 1. PRL pituitary adenoma, polycystic ovary syndrome and other serious somatic diseases; 2. a history of neuroleptic malignant syndrome or tardive dyskinesia; 3. suicide ideas or attempts, or aggressive behavior; 4. a history of alcoholism and drug abuse in the past 1 year; 5. currently treated with other endocrine drugs, Chinese medicine and other natural products; 6. a history of allergy to herbal medicine; 7. lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prolactin;Progesterone;Estradiol;FSH;LH;PASNN; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hepatorenal function;glucose, serum lipids;thyroid function; | — |
Countries
China
Contacts
Brains Hospital of Hu'nan Province